KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biomarin Pharmaceutical (BMRN) Cost of Revenue (2017 - 2026)

Biomarin Pharmaceutical's Cost of Revenue history spans 16 years, with the latest figure at $275.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 102.52% year-over-year to $275.7 million, compared with a TTM value of $717.4 million through Dec 2025, up 23.65%, and an annual FY2025 reading of $717.4 million, up 23.65% over the prior year.
  • Cost of Revenue for Q4 2025 was $275.7 million at Biomarin Pharmaceutical, up from $140.1 million in the prior quarter.
  • The five-year high for Cost of Revenue was $275.7 million in Q4 2025, with the low at $103.5 million in Q3 2021.
  • Average Cost of Revenue over 5 years is $140.2 million, with a median of $130.5 million recorded in 2023.
  • Year-over-year, Cost of Revenue crashed 45.16% in 2021 and then skyrocketed 102.52% in 2025.
  • Tracing BMRN's Cost of Revenue over 5 years: stood at $119.8 million in 2021, then increased by 22.46% to $146.6 million in 2022, then dropped by 5.94% to $137.9 million in 2023, then fell by 1.3% to $136.1 million in 2024, then surged by 102.52% to $275.7 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Cost of Revenue are $275.7 million (Q4 2025), $140.1 million (Q3 2025), and $150.1 million (Q2 2025).